Immuno-Oncology Assays Market Size, Share & Trends Analysis Report By Products & Services (Consumables, Instruments, Software & Services), By Technology (PCR, Immunoassay, NGS, ISH, Flow Cytometry), By Indication (Lung Cancer, Breast Cancer, Colorectal Cancer, Bladder Cancer, Melanoma, Others), By Application (Research Applications, Clinical Diagnostics) and By Region (North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2026-2034

Immuno Oncology Assays Market Size

The global immuno-oncology assays market size was valued at USD 6.16 billion in 2025 and is projected to grow from USD 6.94 billion in 2026 to USD 18.01 billion by 2034, registering a CAGR of 12.66% during the forecast period from 2026 to 2034. North America dominated the immuno-oncology assays market with a market share of 41.98% in 2025.

Products & Service Insights

Consumables dominated the products and services segment with a share of 62.45% in 2025. Consumables have recurring usage across immuno oncology testing workflows, including reagents, antibodies, assay kits, and staining components. Use of specialized consumables in next-generation sequencing and multiplex immunoassays also increases the volume of consumables used per test. An expanding research and clinical trial base is also expected to drive segment growth.

The software & services segment is expected to register a CAGR of 13.22%, as immune profiling workflows increasingly rely on advanced data analysis, immune mapping, and assay interpretation platforms. Software platforms enable easier understanding and integration of complex data released from multiple assay types. A rapid adoption of AI-driven tools to classify immune cell types and integrate multi-omics for holistic profiling is also expected to drive segment growth.

Request Customizationto receive a tailored report.

Technology Insights

PCR led the technology segment with a share of 28.75% in 2025. The segment growth is driven by the widespread use of PCR in immune gene expression analysis, checkpoint marker quantification, and cytokine profiling. Compared to complex assays, PCR is more cost-effective, offers rapid results, and supports versatile applications such as gene expression profiling and treatment monitoring.

The NGS segment is expected to have a CAGR of 13.67% during the forecast period, as immune repertoire profiling and tumor immune interaction analysis gain traction. Expanding use of sequencing-based assays for T cell receptor diversity neoantigen assessment and immune response tracking across immunotherapy programs. This drives higher adoption of NGS within research and translational oncology environments.

Indication Insights

Lung cancer dominated the indication segment in 2025 with a share of 33.67% due to high adoption of immune checkpoint inhibitors and biomarker-guided treatment strategies in lung oncology. Extensive use of PD L1 for immune profiling, tumor microenvironment analysis, and response monitoring assays across lung cancer management pathways sustains strong assay demand.

The breast cancer segment is expected to lead the indication segment with a CAGR of 13.88% during the forecast period. The use of immunotherapy is expanding to broader treatment regimes. Breast cancer treatment highly relies on biomarker profiling, such as HER2 status, hormone receptors, and PIK3CA. Monoclonal antibodies and antibody drug conjugates are showing positive results in triple-negative breast cancer and HER2-positive disease. With the rising cases of breast cancer, the use of such assays is expected to increase, thus expanding segment growth.

Application Insights

Research applications dominate the application segment, driven by extensive use of immuno oncology assays across biomarker discovery, immune mechanism studies, and therapy development programs.

The clinical diagnostics segment is emerging as the fastest-growing application segment, with a CAGR of 13.63%, as immune-based biomarkers are gaining integration into oncological diagnostic workflows. A shift toward precision oncology, customized regimes supports the use of biomarkers in clinical diagnostics. The increasing need for accurate and standardized testing by clinicians is expected to drive segment growth.

Speak to an Analystto discuss market opportunities.

Regional Analysis

The immuno oncology assays market in North America held the largest share of 41.98% in 2025 due to widespread integration of immune biomarker testing across oncology research clinical trials and routine cancer diagnostics. Structured reimbursements, laboratory accreditation standards, and strong linkage between academic cancer centers and diagnostic laboratories support sustained assay utilization across the region. National cancer programs emphasize biomarker-driven oncology care, which anchors immune profiling within standard treatment pathways.

The US leads the regional adoption of immuno oncology assays due to a robust network of oncology research institutions and diagnostic laboratories. The National Cancer Institute outlines extensive use of immune biomarker assays across federally funded immunotherapy trials. Companies such as Roche Diagnostics are also expanding immuno oncology assay deployment across US pathology laboratories, supporting immune checkpoint evaluation and companion diagnostic testing.

Unlock Regional Insightsto access country-level data, & regional trends.

Asia Pacific

Asia Pacific is expected to record the fastest growth trajectory with a CAGR of 14.66% during the forecast period. The Asia Pacific immuno oncology assays market is driven by an expanding oncology infrastructure and the rising incorporation of immune-based testing within national cancer control programs. Governments across the region prioritize molecular and immune diagnostics within tertiary hospitals, while academic institutions scale translational oncology research capacity. Growth in domestic assay manufacturing and regulatory streamlining further supports wider assay availability.

China is expected to be a major contributor in the Asia Pacific market, supported by an increasing focus on preventing cancer and upgrading cancer care in the existing healthcare infrastructure. Under the Healthy China 2030 policy, early diagnosis and precise treatment of cancer have become prime focuses of the government. The government is also supporting the development of immunotherapies and companion diagnostics such as PD L-1, which leads to higher demand for immuno oncology tools. Continuous upgrades in tertiary health facilities, oncology centers, and pathology labs are expected to make the deployment of assays easier in a well-established setup.

Europe

The immuno oncology assays market in Europe is supported by structured public healthcare systems and coordinated oncology diagnostics frameworks. Standardized pathology practices and national cancer registries promote consistent adoption of immune biomarker testing within oncology workflows. Public funding for immunotherapy and biomarker assessment sustains assay demand across both academic and community hospitals.

Germany is expected to lead the Europe immuno oncology assays market due to advanced pathology infrastructure. The European Medicines Agency reinforces biomarker-aligned oncology treatment approaches across the country. Cancer treatment centers in the country are adopting biomarker-driven and immune-guided treatment protocols, which pushes routine use of assays in clinical diagnostics. The robust presence of biotechnology companies also leads to increased demand for standardized assays for manufacturing cell-based therapies. All these factors are expected to propel the immuno oncology assays market growth in Germany.

Middle East and Africa

The Middle East and Africa immuno oncology assays market is shaped by increasing investments in oncology centers and rising adoption of advanced cancer diagnostics within public hospitals. Governments emphasize cancer burden reduction through improved diagnostic access, which supports integration of immune profiling assays within tertiary care facilities. Expansion of oncology training programs further supports assay utilization across the region.

Saudi Arabia leads regional adoption of immuno oncology assays, driven by centralized healthcare funding and national oncology expansion strategies. The Saudi Ministry of Health offers structural support for immuno oncology testing with an increasing investment in advancing healthcare infrastructure and diagnostic tools.

Latin America

The Latin America immuno oncology assays market showcases steady growth, supported by modernization of public oncology services and a rising focus on biomarker-guided cancer treatment. National health systems invest in centralized diagnostic laboratories to improve access to advanced oncology testing. Public procurement frameworks play a central role in expanding assay penetration across urban cancer centers, which propels market growth.

Brazil dominates the Latin American market due to favorable government support and expanding capabilities of local players. The Ministério da Saúde's federal programs support molecular and immune diagnostics in oncology care. Companies such as Dasa are also reporting expansion of immuno oncology testing capabilities across their national laboratory network supporting immune biomarker evaluation.

Competitive Landscape

The immuno oncology assays market is moderately consolidated and is characterized by the presence of established diagnostics manufacturers and specialized molecular and immunodiagnostic companies. Market competition is defined by assay sensitivity and specificity biomarker coverage, such as PD-L1 MSI. Market players also focus on offering assays compatible with companion diagnostic and laboratory-developed test workflows. Leading players maintain their position through broad assay portfolios, strong regulatory clearances, and close alignment with pharmaceutical immunotherapy pipelines. Competitive strength is further influenced by the integration of assays with automated platforms for clinical validation across multiple cancer indications and long-term collaborations with hospitals, reference laboratories, and oncology research centers.

List of Key and Emerging Players in Immuno-Oncology Assays Market